This association was stronger when adjusted for other known prognostic variables and there was a statistically significant increased risk of disease recurrence following a negative SLNB for patients with either a BRAF or NRAS mutant tumour compared to those with wild-type tumours (aHR 1.92, 95% CI 1.02–3.60, p = 0.04). The gene discussed is BRAF; the disease is neoplasm.